REG - Novacyt S.A. - Court sanction of the Scheme of Arrangement

Novacyt SAAnnouncement

07/09/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230907:nRSG7518La&default-theme=true

RNS Number : 7518L  Novacyt S.A.  07 September 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Court sanction of the Scheme of Arrangement

 

Paris, France and Eastleigh, UK - 7 September 2023 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes
today's announcement by Yourgene Health plc ("Yourgene"), in relation to the
recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a
wholly-owned subsidiary of Novacyt, for the entire issued and to be issued
share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which
is to be effected by means of a Court-sanctioned scheme of arrangement under
Part 26 of the Companies Act 2006 (the "Scheme"). A circular in relation to
the Scheme was published by Yourgene on 27 July 2023 (the "Scheme Document").

 

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meaning as set out in the Scheme Document.

 

Further to the announcement made by Yourgene on 17 August 2023 in relation to
the passing of the Resolutions required to approve and implement the Scheme at
the Court Meeting and the General Meeting, Yourgene has announced that at the
Court Sanction Hearing held earlier today the Court issued the Court Order
sanctioning the Scheme.

 

There has been no change to the expected timetable of principal events for the
Acquisition set out in the Scheme Document. Yourgene's full announcement
regarding the Court Sanction Hearing, including detailed next steps and
timetable, can be found here:
https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/rmv3p9r
(https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/rmv3p9r)

 

 

Contacts

 

 Novacyt SA                                                +44 (0)23 8074 8830
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to           +44 (0)20 7260 1000
 Novacyt UK)
 Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)          +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Allegra Finance (French Listing Sponsor)                                                 +33 (1) 42 22 10 10

                                                                                       r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                                                           y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and
Eastleigh, UK, and is listed on the London Stock Exchange's AIM market
("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services
business, enabling the delivery of genomic medicine. The Group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic and screening solutions, for reproductive health
and precision medicine. The Group's portfolio of in vitro diagnostic products
includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other
genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy
tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger®
Technology offers next generation size selection with a range of sample
preparation platforms for dynamic target enrichment. Ranger® Technology can
be utilised to improve workflows and performance in multiple applications
including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service
from UK and Taiwan focusing on precision medicine and reproductive health,
including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN".

 

For more information visit https://yourgenehealth.com/
(https://yourgenehealth.com/)  and follow us on twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SOABBGDCCBGDGXR